Aptose Biosciences announced the results of its reconvened annual and special meeting of shareholders held on August 22, 2025.
Shareholders voted in favor of the appointment of Ernst & Young LLP as the Company's independent auditor.
The Company also received an additional advance from Hanmi Pharmaceutical to continue the development of Tuspetinib in triplet therapy for AML.
New Auditor Appointment
Shareholders voted in favor of Ernst & Young LLP as the Company's new independent auditor.
Funding from Hanmi Pharmaceutical
Aptose received an additional advance of US$1.5 million from Hanmi Pharmaceutical for clinical development.
Tuspetinib Development
Tuspetinib is being developed as a frontline triplet therapy for newly diagnosed AML patients.
- The appointment of Ernst & Young LLP reflects Aptose's commitment to transparency and growth.
- The funding from Hanmi Pharmaceutical will support the continued clinical development of Tuspetinib.
- Developing Tuspetinib as a frontline triplet therapy could address unmet medical needs in oncology, particularly in hematology.
Aptose Biosciences continues to advance in precision oncology with innovative therapies like Tuspetinib, supported by strategic partnerships and shareholder confidence in the Company's direction.